We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01597440
Recruitment Status : Terminated (insufficient enrollment)
First Posted : May 14, 2012
Results First Posted : April 26, 2017
Last Update Posted : April 26, 2017
Information provided by (Responsible Party):

May 10, 2012
May 14, 2012
June 20, 2016
April 26, 2017
April 26, 2017
September 2012
February 2015   (Final data collection date for primary outcome measure)
Neurodevelopment [ Time Frame: 30 months ]
Neurodevelopmental outcome as measured by Cognitive Composite (Bayley III), Motor Composite (Bayley III) and Functional Status Scale and safety of NCG treatment as measured by adverse events and laboratory blood tests
Neurodevelopment [ Time Frame: Intake through 7 days or discharge ]
Neurodevelopmental outcome as measured by Cognitive Composite (Bayley III), Motor Composite (Bayley III) and Functional Status Scale and safety of NCG treatment as measured by adverse events and laboratory blood tests
Complete list of historical versions of study NCT01597440 on ClinicalTrials.gov Archive Site
Number of Participants With Adverse Events [ Time Frame: Start of episode through 7 days or discharge (if earlier) ]
Safety is measured by tracking and detailing the number and type of adverse events and their severity based on the CTCAE.
Safety and Efficacy [ Time Frame: Intakle through 7 days or discharge ]
Safety as measured by adverse events. Efficacy as measured by resolution of hypoammonemia.
Not Provided
Not Provided
Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia
Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

Background: Very few drugs exist that treat hyperammonemia, specifically PA and MMA. Diet restrictions and alternate pathway agents are the current primary treatments, but they frequently fail to prohibit brain damage.

Orthotopic liver transplantation cures the hyperammonemia of urea cycle disorders, but organ availability is limited and the procedure is highly invasive and requires life-long immunosuppression.

A drug that could repair or stimulate a dysfunctional urea cycle such as this would have several advantages over current therapy. A drug called N-carbamyl-L-glutamate, Carglumic acid (NCG or Carbaglu)has recently been found to be virtually curative of another urea cycle defect called NAGS deficiency. In this disorder, treatment with NCG alone normalizes ureagenesis, blood ammonia and glutamine levels, allows normal protein tolerance and restores health. Knowledge from this study is being applied to acquired hyperammonemia, specifically in patients with propionic PA and MMA, to try and improve neurodevelopmental outcomes by improving the hyperammonemia.

Aims: The overall objective of this project is to determine whether treatment of acute hyperammonemia with Carglumic acid in propionic acidemia (PA), methylmalonic acidemia (MMA) changes the long-term outcome of disease and to determine if it is effective in restoring urine ammonia levels to normal levels.

Methods/Design This 5-year, Phase II, double-blind study aims to recruit and enroll 34 PA and MMA patients during acute episodes of hyperammonemia.

The primary aim is to circumvent the long-term neurodevelopmental decline due to having a prolonged levels of ammonia during crisis in the blood and urine. After treatment and crisis resolution with Carbaglu or placebo and standard of care therapy, measures of neurodevelopmental outcomes (Bayley II and Functional Status Scale) are being measured at 9, 15,21 and 30 months post-discharge from the hospital. Safety of NCG treatment will also be monitored as measured by close examination of adverse events and laboratory blood tests. To test for the effectiveness of NCG, longitudinal models to evaluate the groupwise difference (NCG vs. Placebo) in the trajectory of change in neurodevelopmental outcomes and safety analyses between drug and placebo patients.

Subsequent Episodes At any time after the initial episode, participants may present to the hospital with PA- or MMA-associated symptoms. If the plasma ammonia level verified as a bonafide episode of HA (plasma ammonia is ≥ 100 µmol/l), that participant will receive the same study medication that they received during their initial episode in a double-blinded fashion, (i.e. If the participant received NCG at the time of initial randomization, he/she will continue to receive NCG at each subsequent HA episode. If the participant received PLBO at the time of initial randomization, he/she will continue to receive PLBO at each subsequent HA episode). Only the pharmacist will know if the participant receives NCG or PLBO. The same study assessments (previously stated) will be conducted at each qualifying HSA episode.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Propionic Acidemia
  • Methylmalonic Acidemia
  • Drug: N-carbamylglutamate

    Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).

    The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.

    This drug will be administered for 7 days after admission or until discharge (whichever is sooner).

    Other Names:
    • Carbaglu
    • NCG
  • Other: Standard of Care
    Standard of Care
  • Experimental: N-Carbamylglutamate
    Active NCG & Standard of Care
    • Drug: N-carbamylglutamate
    • Other: Standard of Care
  • Placebo Comparator: Placebo
    Standard of Care therapy
    Intervention: Other: Standard of Care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2015
February 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Aged 4 weeks or younger (0-28 days)
  • >36 weeks gestational age at birth
  • Birth weight ≥2500 g
  • Plasma ammonia level at presentation >150 mcmol/L
  • PA or MMA presumed or established diagnosis as follows (one of the following):

    1. Acidosis at presentation, pH <7.3 OR
    2. Plasma acylcarnitine analysis either alone or as part of newborn screening, demonstrating C3 >4 mcmol/L OR
    3. Diagnosed, or sibling diagnosed with PA by semi-quantitative urine organic acid analysis, defined as presence of elevated methylcitric acid and no evidence of biotin related disorders in the organic acid analysis OR
    4. Diagnosed, or sibling diagnosed with MMA by semi-quantitative urine organic acid analysis, defined as elevation of methylmalonic acid and no evidence of vitamin B12 dependent disorder on plasma amino acid analysis
  • Able to receive medications orally, by nasogastric (NG)-tube or by gastric (G)-tube
  • No concomitant illness which would preclude safe participation as judged by the investigator
  • Signed informed consent by the subject's legally acceptable representative
  • After initial enrollment, criteria 3 or 4 (definitive diagnosis of the patient) must be fulfilled prior to discharge from initial admission in order to remain in the study.

Exclusion Criteria

  • Had any prior hyperammonemic episode
  • Administration of NCG within 7 days of participation in the study
  • Use of any other investigational drug, biologic, or therapy, with the exception of sodium benzoate or sodium phenylacetate if the latter were administered prior to diagnosis by acylcarnitine analysis (diagnostic inclusion criterion 2), or organic acid analysis (diagnostic inclusion criteria 3 & 4)
  • Planned participation in any other clinical trial
  • Diagnosis of any medical condition causing hyperammonemia which is not PA or MMA.
  • Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at an additional risk by participating in this study
  • Had a liver transplant or is scheduled for a liver transplant
  • Is not expected to be compliant with this study in terms of returning to site for subsequent episodes of hyperammonemia crises or for long-term follow-up
Sexes Eligible for Study: All
up to 4 Weeks   (Child)
Contact information is only displayed when the study is recruiting subjects
United States
NCGC 0007
Not Provided
Plan to Share IPD: No
Plan Description: A single participant was enrolled before the study closed. There are no analyses and if data are shared, this may compromise the confidentiality of this single participant from a very rare disease.
Mendel Tuchman, Children's Research Institute
Mendel Tuchman
  • Children's Research Institute
  • Boston Children’s Hospital
  • University Hospitals Cleveland Medical Center
  • University of California, Los Angeles
  • Children's Hospital of Philadelphia
  • Lucile Packard Children's Hospital
  • University of Colorado, Denver
Principal Investigator: Mendel Tuchman, MD Children's Research Institute
Children's Research Institute
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP